

Kawamura M, Ohara S, Iijima K, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. *Aliment Pharmacol Ther.* 2003;19:965-973 .

Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. *BMJ* 2012; 344:e372.

Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. *Drugs.* 1995;49:695-710.

Kubin M, Wagner G, Fugi-Meyer AR. Epidemiology of erectile dysfunction. *Int J Impot Res.* 2003;15:63–71 .

Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, et al. Atrophic gastritis and *Helicobacter pylori* infection in patients with reflux esophagitis treated with omeprazole or fundoplication. *N Engl J Med.* 1996;334:1018–22.

Kulkarni S., Tripathi S., Mehta P D., Lodhi N.S., Sengar N.P.S. Esomeprazole In The Treatment Of Acidic Disorder : An Overreview, *Asian J Bioch and Pharmaceutical Research* Issue 2 (Vol. 1) 2011 562 .